

The protective effect of dexamethasone and lactate against cisplatin-induced ototoxicity*

Arif ŞANLI¹, Sedat AYDIN¹, Zeynep Alev SARISOY², Mustafa PAKSOY¹, Emin AYDURAN³,
Özlem ÇELEBİ ERDİVANLI⁴

Aim: To compare the protective effect of dexamethasone and lactate against cisplatin-induced ototoxicity.

Materials and methods: Thirty Wistar rats were randomly divided into 4 groups. After the rats were sedated with intraperitoneal (IP) ketamine hydrochloride (50 mg/kg) and xylazine (7.5 mg/kg), baseline ABRs (auditory brainstem evoked responses) were measured in response to clicks and tone pips of 4, 8, 12, and 16 kHz. After auditory thresholds were determined, the animals received drug administration as follows: Group 1 (n: 6) received intratympanic (IT) saline (0.9% NaCl) solution, Group 2 (n: 8) IP cisplatin (20 mg/kg) alone, Group 3 (n: 8) IT dexamethasone (0.1-0.3 mL), and Group 4 (n: 8) IT lactated Ringer's (LR) solution (0.1-0.3 mL) followed after 30 min by 20 mg/kg cisplatin. Dexamethasone, LR solution, and saline application were continued for 3 days. At the end of the study, ABR testing was performed and threshold changes were recorded.

Results: Group 2 animals showed marked hearing loss with average threshold shifts of 39,6 dB for clicks, 7,2 dB at 4 kHz, 8,4 dB at 8 kHz, 71,1 dB at 12 kHz and 71,8 dB at 16 kHz. No significant loss was observed in Group 3 with average threshold shifts of 1,6 dB, 4,7 dB, 8,7 dB, and 4,2 dB for clicks and tone pips at 4, 8, 12, and 16 kHz, respectively. Similar findings were observed in Group 4 with shifts of 3,5 dB, 6,8 dB, 11,3 dB, and 15,2 dB for clicks and tone pips at 4, 8, 12, and 16 kHz, respectively. Significant protection was seen in Group 3 and 4 animals compared with Group 2 animals. There was no side effect in IT administration of LR solution and dexamethasone for hearing functions. Both of these appear to be easier and safer to apply and have a usable protective effect against cisplatin ototoxicity.

Conclusion: IT administration of LR solution and dexamethasone appear to be easy and safe to apply and have a useful protective effect. Clinical applications including these agents could be considered for use in order to reduce the side effects of ototoxic chemotherapy protocols.

Key words: Cisplatin, ototoxicity, dexamethasone, lactated ringer's solution, otoprotection, rat, intratympanic route

Sisplatin ototoksitesinde dekzametazon ve laktat'ın koruyucu etkinliği

Amaç: Sisplatin ototoksitesinde intratimpanik deksametazon ve laktatın koruyucu etkinlikleri karşılaştırıldı.

Yöntem ve gereç: Otuz Wistar cinsi sıçan rastgele dört guruba ayrıldı. Sıçanlar intraperitoneal ketamine hydrochloride (50 mg/kg) ve xylazine (7.5 mg/kg) ile sedatize edildikten sonra, Bütün hayvanların uygulamalar öncesinde ABR (Auditory brainstem response) ile 4, 8, 12 ve 16 kHz'de klik ve "tone-pips" uyarılarla bazal işitme eşikleri saptandı. Oditör eşikler saptandıktan sonra, sıçanlara aşağıdaki sırayla ilaçlar uygulandı: 1. Grup (n: 6) intratimpanik % 0,9 salin

Received: 28.05.2010 – Accepted: 28.08.2010

¹ 2nd ENT Department, Kartal Education and Research Hospital, İstanbul - TURKEY

² Giresun Governmet Hospital, Giresun - TURKEY

³ Şırnak Military Hospital, Şırnak - TURKEY

⁴ Rize Government Hospital, Rize - TURKEY

Correspondence: Sedat AYDIN, İstasyon Caddesi, Merdivenli Sokak, Özkan Apt. 5/6 Kartal, İstanbul - TURKEY

E-mail: sedataydin63@yahoo.com

* This article is presented as an oral presentation at the 31st Turkish National Otorhinolaryngology and Head Neck Surgery Congress in Belek, Antalya, Turkey, 2009 (presentation number SS-98)

(NaCl) solusyonu; 2. Grup (n: 8), yalnızca intraperitoneal sisplatin (20 mg/kg); 3. Grup (n: 8) intraperitoneal sisplatin ile birlikte intratimpanik deksametazon (0.1-0.3 mL) ve 4. Grup (n: 8) 20 mg/kg sisplatin uygulamasından 30 dakika sonra intratimpanik Ringer laktat (RL) solusyonu (0.1-0.3 mL) uygulandı Dekzametazon, RL solusyonu ve % 0,9 salin uygulamasına üç gün boyunca devam edildi. Çalışmanın sonunda, ABR testi uygulandı ve eşik değişimleri ölçüldü.

Bulgular: 2. Grup taki sıçanlar uygulama öncesi ve sonrası işitme eşikleri arası ortalama fark 39,6 dB olup 4 kHz de 7,2 dB, 8 kHz de 8,4 dB, 12 kHz de 71,1 dB ve 16 kHz de 71,8 dB lik eşik farkları saptandı. 3. grupta belirgin işitme kaybı gözlenmedi. Klik ve "tone-pips" uyarılara karşı işitme eşikleri arası ortalama fark 4, 8, 12 ve 16 kHz frekansları için sırasıyla 1,60 dB, 4,75 dB, 8,70 dB, ve 4,26 dB olarak ölçüldü. Benzer bulgular 4. grupta da saptandı. Bu grupta klik ve "tone-pips" uyarılara karşı işitme eşikleri arası ortalama fark 4, 8, 12 ve 16 kHz frekansları için sırasıyla 3,56 dB, 6,87 dB, 11,34 dB, ve 15,29 dB olarak ölçüldü. 2. gruba kıyasla 3. ve 4. grup sıçanlarda belirgin olarak işitmenin korunduğu saptandı. Ayrıca işitme fonksiyonları üzerine intratimpanik RL ve deksametazonun herhangi bir yan etkisinin olmadığı ve bu iki ajanın sisplatin ototoksitesinde kolay uygulanabilir, güvenli ve koruyucu olduklarını söyleyebiliriz.

Sonuç: İntratimpanik RL solusyonu ve deksametazon kolay uygulanabilen ve güvenli ajanlardır. kemoterapi protokollerinin ototoksik yan etkilerini azaltmak için klinik uygulamalara bu ajanların dahil edilmesi uygun olacaktır.

Anahtar sözcükler: Cisplatin, ototoksiste, deksametazon, ringer laktat solusyonu, sıçan, intratimpanik yöntem

Introduction

Cisplatin is an effective antineoplastic agent widely used in medullablastoma, neuroblastoma, osteosarcoma, and various cancer treatments (testicular, ovarian, cervix, bladder, lung, and brain) (1). However, there are various side effects related to non-specific cytotoxic influences. A common dose side effect is ototoxicity (2). Cisplatin ototoxicity in adults and children may lead to hearing loss starting as sensorineural tinnitus. Hearing loss begins at high frequencies and then progresses towards lower frequencies, which are crucial for hearing speech (2-4). The resultant hearing loss depends on the dose. Hearing loss may be cumulative, bilateral, and permanent. Some 60% to 80% of patients experience some hearing loss and approximately 15% experience permanent hearing loss (5,6). Cisplatin provides development reactive oxygen species (ROT) as superoxide anions at a molecular level. Glutathione and antioxidant enzymes are released as ROT rise. In this case, superoxide hydrogen peroxide and toxic lipids cause apoptosis with calcium entrance to cochlear cells (7-9). Many experimental studies have been done to find the most suitable otoprotective agent mostly as an antioxidant supplement against ROT at early stages of ototoxicity (10). Unfortunately, most of these agents inhibit antitumoral effects of cisplatin (1). As a result, there are no clinical agents that prevent cisplatin ototoxicity at present.

Glucocorticoids (GCs) are used in hearing loss treatment for various cochlear diseases when the etiology is not clear as in otoimmune inner ear

disorder, endolymphatic hydrops, Ménière's disease, tinnitus, and sudden or idiopathic rapidly progressing hearing loss (11). It has been shown that the existence of GCs receptors in the rat's inner ear structure is effective in limiting steroid ROT development (12-14). The protective effect of lactated Ringer's (LR) solution is not known yet. However, it is thought that LR solution is effective via nicotinamide adenine dinucleotide (NADH). Lactate dehydrogenase H isoenzyme (LDH-H), which is the originator of the endogenous antioxidant NADH converts lactate into pyruvate.

It has been shown that cisplatin doses do not cause LDH inhibition in clinical or experimental studies. At the same time, perilymph concentrations of LDH and lactate are found 3 times more than those of blood or cerebrospinal fluid (15,16).

One of the aims of the experiment described herein was to identify a laboratory animal that would be ototoxically susceptible and consequently would have the potential to be used as a model in the study of early effects of cisplatin on auditory function. For this purpose, we used Wistar rats as an animal model to determine the ototoxicity of cisplatin. Cisplatin was systemically administered with 2 high doses to rats, and the ototoxic effects were evaluated. If ototoxicity occurs, it can be prevented by IT administration of dexamethasone or LR solution. In addition, this study investigated the role of auditory brainstem evoked response (ABR) as an indicator of cisplatin-induced ototoxicity and ABR thresholds were used to compare the ototoxicity in these animals.

Materials and methods

This study was approved by the Committee for Ethics in Animal Experiments of the Current Haydarpaşa Numune Training and Research Hospital with protocol number (13/2009). Thirty healthy Wistar rats (190-300 g) were housed in temperature controlled rooms with 12-h light/dark cycles. These animals were provided with free access to food and water. They were allowed to acclimatize to their cages for at least 48 h after shipment. They were sedated using an intraperitoneal (IP) solution of 50 mg/kg ketamine hydrochloride (Ketalar, Eczacıbaşı, Turkey) and 7.5 mg/kg xylazine (Rompun, Bayer, Germany). Rectal temperatures were continuously monitored while the animals were under anesthesia. The animals were also placed on a warming blanket calibrated to maintain body temperature at 35 °C. The rats were divided into 4 study groups after baseline ABR testing was performed (Table 1). All tympanic membranes were examined with an operating microscope (Zeiss, S1, Germany) before earphone placement to ensure normal middle ear appearance.

Group 1: (6 rats, 12 ears) Saline (0.9% NaCl) solution was selected as the control agent because it is the solvent in which dexamethasone was stored and administered for 3 days.

Group 2: (8 rats, 16 ears) cisplatin 20 mg/kg was given as an IP infusion (Cisplatin-teva 10 mg 1 flakon, Med-ilac, İstanbul, Turkey) for 2 days.

Group 3: (8 rats, 16 ears) cisplatin 20 mg/kg was given IP as a slow infusion and rats received 4 mg/kg IT dexamethasone (Onadron flakon, I.E. Ulagay, İstanbul, Turkey), followed after 30 min and 24 h by an IP infusion of cisplatin. This was administered

under an operating microscope, slowly through a myringotomy in the anterosuperior quadrant, with a 28-gauge dental needle to fill the middle ear cavity (approximately 0.1 to 0.3 mL). After keeping the animal in the same position for 30 min, the procedure was performed in the other ear.

Group 4: (8 rats, 16 ears) received intratympanic (IT) LR solution (lactate, 28 mEq/L) (approximately 0.1 to 0.3 mL) (Eczacıbaşı-Baxter, İstanbul, Turkey), followed after 30 min and 24 h by IP cisplatin.

After an observation period of 3 days, the animals were again sedated and follow-up ABR testing was performed to determine the degree of threshold change compared with baseline measures. No tympanic membrane perforations or complications were observed as a result of these procedures.

Auditory brainstem evoked responses testing

A total of 30 rats were used for ABR recording. Rats were sedated with xylazine and ketamine. Baseline ABRs were measured using the Smart EP evoked potential system (Intelligent Hearing Systems, Miami, FL, USA). Responses to 100 µs clicks and tone pips with an 8-ms plateau and a 1-ms rise fall time at 4, 8, 12, and 16 kHz were averaged using this instruments signal generating averaging system. The stimuli were presented inside a double-walled radio frequency-shielded sound booth using an Etymotic ER-2 earphone placed directly into the ear canal. Clicks and tone pips were presented at a rate of 5 times per second. Animals were presented with a stimulus intensity series, which began at 10 dB sound pressure level (SPL) and reached a maximum of 90 dB SPL. Stimulus intensity was progressively increased in 10 dB increments. Resulting ABRs were observed on a

Table 1. Distribution of rats and application numbers according to study groups.

Groups	Used procedure	Description	The rats (n)	Applications (n)
1	IT. saline solution	Negative control with IT injection	6	3
2	IP. cisplatin	Ototoxicity group	8	2
3	IP. cisplatin with IT.dexamethasone	Treatment group	8	5
4	IP. cisplatin with IT. lactate	Treatment group	8	5

video monitor. Intensities that appeared to be near threshold were repeated. Threshold was defined as the lowest intensity capable of producing a visually detectable, reproducible response. The voltage associated with threshold was 0.5 μ V. Subdermal electrodes were used to record brain potentials differentially. The active electrode was positioned at the vertex and the reference electrode at the mastoid tip contralaterally. The ground electrode was located over the mastoid tip ipsilaterally. Potentials were amplified 1000 times inside the sound attenuation booth (bandwidth 0.1-10 kHz), and signals were further amplified to produce an overall gain of nearly 100,000 and viewed on an oscilloscope. The ABR were sampled for 20.5 ms after stimulus onset. Stimuli were repeated 5 times per second, and a total of 512 trials were averaged using an analog to digital converting system. After an observation period of 3 days, the animals were again sedated, and underwent follow-up ABR testing to determine the degree of threshold change from baseline.

Statistical analysis

NCSS 2007 & PASS 2008 Statistical Software (Utah, USA) was used. This software suggested that a sample size of 30 animals would be sufficient for statistical significance. Considering possible unforeseen events resulting in the loss of animals during the study, we used 30 animals in 4 groups of 6, 8, 8, 8, i.e. 30 animals were randomly assigned to

4 groups, each group including 16 ears, except the control group. The data were analyzed using the Wilcoxon paired 2-sample test, Mann-Whitney U test, and Kruskal-Wallis variance analysis in SPSS 11.0 for Windows. A P value of less than or equal to 0.05 was considered significant.

Results

ABR threshold shifts for clicks were compared following drug administration; the results are shown in Table 2. No significant change in hearing was seen in animals receiving saline (Group 1) with shifts of 1.1 dB, 1.4 dB, 2.5 dB, and 3.3 dB for clicks at 4, 8, 12, and 16 kHz, respectively. There were no significant differences in the ABR thresholds ($P > 0.05$) after administration of saline. The injections had no toxic effect on cochlear emissions in any of the rats. Marked hearing loss was noted in animals receiving cisplatin (Group 2) with average threshold shifts of 39.6 dB for all frequencies, 7 dB at 4 kHz, 8 dB at 8 kHz, 7 dB at 12 kHz, and 7 dB at 16 kHz. Differences in ABR thresholds at frequencies 4 to 8 kHz were not statistically significant (4 kHz $P = 0.17$, 8 kHz $P = 0.08$). However, ABR thresholds decreased significantly at frequencies 12 to 16 kHz 3 days after IP cisplatin injection (12 kHz $P = 0.003$, 16 kHz $P = 0.003$) (Figure). A significant degree of otoprotection was observed in Group 3 animals with average threshold

Table 2. Mean hearing levels (dB) before (pre) and after (post) drug administration.

Hearing frequencies		Group 1	Group 2	Group 3	Group 4
		dB	dB	dB	dB
4 kHz	Pre	12	16	23	23
	Post	13	23	24	26
8 kHz	Pre	10	13	12	21
	Post	11	22	17	28
12 kHz	Pre	31	15	34	37
	Post	33	86	43	48
16 kHz	Pre	28	16	32	32
	Post	31	88	36	48




Figure. Mean hearing levels (dB) before (pre) and after (post) drug administration.

shifts of 4.8 dB for all frequencies, 1 dB for 4 kHz, 4 dB for 8 kHz, 8 dB for 12 kHz, and 4 dB for 16 kHz. Moreover, a significant degree of otoprotection was observed in Group 4 animals with average threshold shifts of 9.2 dB for all frequencies, 3 dB for 4 kHz, 6 dB for 8 kHz, 11 dB for 12 kHz, and 15 dB for 16 kHz (Table 3). In Group 3 as well as in Group 4, there were no significant differences in ABR thresholds before and after administration of IT dexamethasone or RL solution ($P > 0.05$) suggesting that IT dexamethasone or RL solution had an otoprotective effect in subjects given 2 high doses of cisplatin ($P < 0.01$).

Discussion

Cisplatin is now the most widely used anticancer drug for a variety of human neoplasms especially

for squamous cell carcinoma of the head and neck. However, it is an antineoplastic agent with an ototoxic side effect. Factors affecting the incidence of ototoxicity are application route, cumulative dose, age, dietary factors, plasma protein level, genetic factors, and cranial radiotherapy history. The ototoxic effect usually appears on the 2nd day of treatment and may continue up to 7 days after treatment (1-4).

The ototoxicity of cisplatin first appears histopathologically on the first row of cells on the curve of the cochlea then moves upwards towards the outer hair cells and damages inner hair cells together with the organ of corti, spiral ganglion, and stria vascularis (10,17-19). Nitric oxide (NO) occurrence is blamed for the ototoxicity of cisplatin, which is a result of excessive production of ROT and nitric oxide synthase (NOS) (20).

Table 3. The hearing loss average shift levels (dB) before and after drug application.

Frequencies	Group 1 dB	Group 2 dB	Group 3 dB	Group 4 dB
4 kHz	1.10	7.25	1.60	3.56
8 kHz	1.45	8.44	4.75	6.87
12 kHz	2.55	71.12	8.70	11.34
16 kHz	3.35	71.83	4.26	15.29

Many studies have been conducted concerning the ototoxicity of cisplatin. Clinical studies done in the last 8-10 years have shown that L- and D-methionine, sodium thiosulfate, ebselen, and 4-methylthiobenzoic acid are significant effective agents (21-27). These agents are used locally or systemically. Reduction of cisplatin anti-tumor activity is observed in animal studies during the course of systemic antioxidant application except for ebselen (27). Animal studies have shown that GCs reduce NO related harm on cochlear cells in ototoxicity of cisplatin and aminoglycoside ototoxicity, which are estimated to have similar pathogenesis and protective effects as well as inhibiting release of reactive nitrogen mediator (14,28). In this respect, GCs are used as IT as a current method in local inner ear treatment. Diffusion to the inner ear spreads through the round window membrane. In this manner, GCs can provide a higher concentration in the inner ear compared to other oral or parenteral routes. It was found that an IT injection of methylprednisolone produced perilymph concentrations that were 33-fold higher and plasma concentrations that were 136-fold lower than the respective concentrations from parenteral dosing (29). Separately local administration prevents systemic absorption, avoiding the common systemic side effects of steroids including hyperglycemia, peptic ulcers, hypertension, osteoporosis, and more problematic reduced efficacy of chemotherapeutic agents (11,14).

GCs have been used to safely and widely treat other inner ear disorders such as sudden sensorineural hearing loss and Ménière's disease for several years (11). Daldal (28) and Hill et al. (30) demonstrated the protective effect of IT dexamethasone against cisplatin-induced ototoxicity in guinea pigs and IT dexamethasone had no ototoxic or systemic side effects on DPOAE measurements. The present study suggests that dexamethasone does not have a side effect on cochlear function, and the findings concur with those of recent studies.

We hypothesize that IT dexamethasone may also have a place for preventing cisplatin ototoxicity. We used local application to exclude possible adverse effects of systemic application and to achieve a higher concentration of dexamethasone in the cochlear fluid more rapidly. Only 0.1 to 0.3 mL was enough to

cover the round window, although sampling from the inner ear for the measurement of the diffused drug concentration was not done. In the present study, there were no significant differences in the pre- and post-drug injection measurements of ABR threshold shifts to the click in Group 3.

Even though lactate's protective action is not clearly explained yet, current evidence shows that cisplatin and lactate (in the form of LR solution) may have important effects on outer hair cell metabolism, both revolving around the depletion and repletion of intracellular NADH, which is an endogenous antioxidant. Of the other components of LR solution, lactate is the most likely to provide the protective role. All of the other components have been found to have either equivocal or potentiating effects on cisplatin ototoxicity (15). In a study of protectivity of LR solution and N-acetylsysteine, these 2 substances are given by IT method to guinea pigs simultaneously after creating cisplatin ototoxicity. The N-acetylsysteine applied group demonstrated mid-grade improvement in their hearing level but the LR solution applied group demonstrated nearly full improvement. This study explains that the reason for lactate's otoprotective effect being higher is the lower molecular weight of lactate compared with N-acetylsysteine, allowing it to pass through the round window membrane more easily (15). We also found that there were no statistically significant differences in hearing threshold shifts after administration of cisplatin in the LR solution applied group. In the present study, there were no significant differences in the pre- and post-drug injection measurements of ABR threshold shifts for the click in Group 3, but we observed that the dexamethasone applied group demonstrated more improvement in their hearing level compared to the LR solution applied group ($P > 0.05$).

In the present study no differences were found in the average ABR thresholds for Groups 1, 3, and 4 before and after application. However, significant differences were observed especially at 12 and 16 kHz for Group 2, which indicates the side effect of cisplatin's ototoxicity. The present study demonstrated a smaller hearing loss after application of cisplatin for Groups 3 and 4 related to dexamethasone and LR solution having a protective effect over cisplatin's ototoxicity. Our findings support a few articles in the

literature written about this issue. Moreover, we used ABR testing, which measures threshold, as opposed to using otoacoustic emissions.

In our study we used dexamethasone and LR solution because there was no research comparing the effectiveness of these 2 agents in relation to cisplatin's

ototoxicity. There have been concerns about IT treatment in recent years. Knowledge gained from this kind of experimental application with several agents could be readily transferred into clinical practice to increase the safety of cancer treatments in the future.

References

- Rybak LP, Whitworth CA. Ototoxicity: therapeutic opportunities. *Drug Discov Today* 2005; 10: 1313-21.
- Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. *Br J Cancer* 1998; 77: 1355-62.
- Ayan N, Ayan İ, Aydın S, Kebudi R, Gürsel AO, Bilge N. Cisplatin tedavisi alan çocuklarda ototoksosite. *Beyoğlu* 1991; 1: 43-9.
- Biro K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I et al. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. *Oncology* 2006; 70: 177-84.
- Laurell G, Jungnelius U. High-dose cisplatin treatment: hearing loss and plasma concentrations. *Laryngoscope* 1990; 100: 724-34.
- Blakley BW, Gupta AK, Myers SE, Schwan S. Risk factors for ototoxicity due to cisplatin. *Arch Otolaryngol Head Neck Surg* 1994; 120: 541-6.
- Clerici WJ, DiMartino DL, Prasad MR. Direct effects of reactive oxygen species on cochlear outer hair cell shape in vitro. *Hear Res* 1995; 84: 30-40.
- Dehne N, Lautermann J, Petrat F, Rauen U, de Groot H. Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. *Toxicol Appl Pharmacol* 2001; 174: 27-34.
- Rybak LP, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. *Am J Otol* 2000; 21: 513-20.
- Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin induced ototoxicity and prevention. *Hear Res* 2007; 226: 157-67.
- Doyle KJ, Bauch C, Battista R, Beatty C, Hughes GB, Mason J et al. Intratympanic steroid treatment: a review. *Otol Neurotol* 2004; 25: 1034-9.
- Kolls J, Xie J, LeBlanc R, Malinski T, Nelson S, Summer W et al. Rapid induction of messenger RNA for nitric oxide synthase II in rat neutrophils in vivo by endotoxin and its suppression by prednisolone. *Proc Soc Exp Biol Med* 1994; 205: 220-9.
- Nagura M, Iwasaki S, Wu R, Mizuta K, Umemura K, Hoshino T. Effects of corticosteroid, contrast medium and ATP on focal microcirculatory disorders of the cochlea. *Eur J Pharmacol* 1999; 366: 47-53.
- Hargunani CA, Kempton JB, DeGagne JM, Trune DR. Intratympanic injection of dexamethasone: time course of inner ear distribution and conversion to its active form. *Otol Neurotol* 2006; 27: 564-9.
- Choe WT, Chinosornvatana N, Chang KW. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. *Otol Neurotol* 2004; 25: 910-5.
- Hannemann J, Baumann K. Inhibition of lactate-dehydrogenase by cisplatin and other platinum-compounds: enzyme leakage of LDH is not a suitable method to measure platinum-compound-induced kidney cell damage in vitro. *Res Commun Chem Pathol Pharmacol* 1988; 60: 371-9.
- Van den Berg JH, Beijnen JH, Balm AJ, Schellens JH. Future opportunities in preventing cisplatin induced ototoxicity. *Cancer Treat Rev* 2006; 32: 390-7.
- Cardinaal RM, De Groot JC, Huizing EH, Veldman JE, Smoorenburg GF. Cisplatin-induced ototoxicity: morphological evidence of spontaneous outer hair cell recovery in albino guinea pigs? *Hear Res* 2000; 144: 147-56.
- Van Ruijven MW, De Groot JC, Klis SF, Smoorenburg GF. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. *Hear Res* 2005; 205: 241-8.
- Watanabe KI, Hess A, Bloch W, Michel O. Nitric oxide synthase inhibitor suppresses the ototoxic side effect of cisplatin in guinea pigs. *Anticancer Drugs* 2000; 11: 401-6.
- Li G, Frenz DA, Brahmblatt S, Feghali JG, Ruben RJ, Berggren D et al. Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. *Neurotoxicology* 2001; 22: 163-76.
- Kopke RD, Liu W, Gabaizadeh R, Jacono A, Feghali J, Spray D, Garcia P, Steinman H, Malgrange B, Ruben RJ, Rybak L, Van de Water TR. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. *Am J Otol* 1997; 18: 559-71.

Protective agents on cisplatin's ototoxicity

23. Kaltenbach JA, Church MW, Blakley BW, McCaslin DL, Burgio DL. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. *Otolaryngol Head Neck Surg* 1997; 117: 493-500.
24. Kamimura T, Whitworth CA, Rybak LP. Effect of 4-methylthiobenzoic acid on cisplatin-induced ototoxicity in the rat. *Hear Res* 1999; 131: 117-27.
25. Korver KD, Rybak LP, Whitworth C, Campbell KM. Round window application of D-methionine provides complete cisplatin otoprotection. *Otolaryngol Head Neck Surg* 2002; 126: 683-9.
26. Church MW, Kaltenbach JA, Blakley BW, Burgio DL. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. *Hear Res* 1995; 86: 195-203.
27. Reser D, Rho M, Dewan D, Herbst L, Li G, Stupak H et al. L- and D- methionine provide equivalent long term protection against CDDP-induced ototoxicity in vivo, with partial in vitro and in vivo retention of antineoplastic activity. *Neurotoxicology* 1999; 20: 731-48.
28. Daldal A, Odabasi O, Serbetcioglu B. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs. *Otolaryngol Head Neck Surg* 2007; 137: 747-52.
29. Hill GW, Morest DK, Parham K. Cisplatin-induced ototoxicity: effect of intratympanic dexamethasone injections. *Otol Neurotol* 2008; 29: 1005-11.
30. Bird PA, Begg EJ, Zhang M, Keast AT, Murray DP, Balkany TJ. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. *Otol Neurotol* 2007; 28: 1124-30.